105ab5be-8512-48fd-aa60-38a2b37bfc64.pdf

Admedus Ltd

ABN 35 088 221 078

ASX ANNOUNCEMENT

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

PO Box 6879

East Perth Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

Einfo.au@admedus.com www.admedus.com

RESIGNATION OF MANAGING DIRECTOR

Brisbane, Australia 23 May 2016

Admedus Limited (ASX:AHZ) has today announced that Mr Lee Rodne has resigned as Managing Director and Chief Executive Officer of Admedus Limited, effective 30 June 2016.

Mr Wayne Paterson, Chairman said, "The Board thanks Mr. Rodne for his leadership and guidance of the Company over the past 10 years and we wish him well in his future endeavours".

Mr Paterson who will act as interim Managing Director added, "We have an experienced senior management team and Board who will work with me to manage the business until the nominations committee selects our new Managing Director."

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

Admedus Ltd. published this content on 23 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 May 2016 18:40:01 UTC.

Original documenthttp://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6776674

Public permalinkhttp://www.publicnow.com/view/8B1C488102CEF0A5A58DB106CE3422D0617C69BB